REG - Roquefort Theraptcs. - Ex-Entitlement Date - Unlisted RNV Shares

Roquefort TherapeuticsAnnouncement

Mon 10:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251201:nRSA6886Ja&default-theme=true

RNS Number : 6886J  Roquefort Therapeutics PLC  01 December 2025

1 December 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Ex-Entitlement Date - Unlisted Redeemable Non-Voting Shares

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company,
announces that further to the Company's announcement earlier today confirming
that the record date for determining entitlement to the Unlisted Redeemable
Non-Voting Shares ("Unlisted RNV Shares") has now passed, its ordinary shares
will be marked ex-entitlement in respect of the Unlisted RNV Shares with
effect from the commencement of trading today, 1 December 2025.

 

Accordingly, all holders of ordinary shares and convertible loan notes who
were on the Company's register as at close of business on 28 November 2025
will be eligible to receive the Unlisted RNV Shares. In addition, anyone who
purchased ordinary shares on Friday, 28 November 2025 will also be eligible to
receive the Unlisted RNV Shares.

 

A detailed timetable for the crediting of the Unlisted RNV Shares to eligible
shareholders, together with full details of the entitlement ratio and the
exact number of Unlisted RNV Shares to be issued, will be set out in a further
announcement to be made in due course.

 

Regulatory Information

This Announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").

 

ENDS

 
Enquiries:
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker to the Company)   +44 (0)20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Shard Capital Partners LLP (Broker to the Company)       +44 (0)20 4530 6926

 Damon Heath
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is focused on completing the proposed
transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which
will result in the Company acquiring the exclusive licence rights to AO-252, a
novel first-in-class, first-in-human new drug alternative targeting the TACC3
protein for the treatment of certain cancers, initially announced by the
Company on 8 September 2025.

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FURUAORRVOUURAA



            Copyright 2019 Regulatory News Service, all rights reserved